Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
741-760 of 998 trials

Hypertrophic Cardiomyopathy: Bisoprolol vs. Verapamil

We are studying the effects of Bisoprolol and Verapamil on symptoms and heart function in patients with non-obstructive hypertrophic cardiomyopathy. Our goal is to see if these treatments can improve exercise capacity and reduce heart rhythm issues.

Non-obstructive Hypertrophic Cardiomyopathy3-6 monthsMonitoring phase (IV)Standard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Steroid Treatment for Wheezing in Children

We are studying whether a new steroid treatment can help prevent asthma in children who wheezed for the first time after a rhinovirus infection. The trial will also look at the frequency and severity of wheezing episodes over time.

Acute Wheezing/Bronchiolitis1-2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

MELAS: Testing Zagociguat

We are studying the investigational drug zagociguat to see if it helps reduce fatigue and improve thinking skills in people with MELAS. The trial also looks at its safety and effects on muscle weakness and memory.

MELAS Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineNeurology

Staphylococcus Aureus Bacteremia: Shorter Antibiotic Treatment

We are studying whether 4 weeks of antibiotic treatment is as effective as 6 weeks for patients with complicated Staphylococcus aureus bacteremia who have improved after initial therapy.

Staphylococcus aureus Bacteremia6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious Diseases

Rett Syndrome: Testing Mirtazapine

We are studying whether Mirtazapine can improve social behavior, anxiety, and sleep quality in patients with Rett syndrome. This research may help us understand how to better manage symptoms of this condition.

Rett Syndrome6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Atopic Dermatitis: RO7790121 Treatment Study

We are testing a new medication, RO7790121, for people with moderate to severe atopic dermatitis. The study aims to see if it can significantly improve skin symptoms compared to a placebo.

Atopic DermatitisEfficacy phase (II)≤5 visitsInvestigational MedicinesPartially RemoteAllergologyDermatology

Preventing Heart Issues in Cancer Patients: Empagliflozin Study

We are studying whether empagliflozin can help prevent heart problems in cancer patients undergoing chemotherapy with anthracyclines. We will compare its effects to a placebo to assess safety and effectiveness.

Cardiotoxicity1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyOncology

Metastatic Urothelial Carcinoma: Livmoniplimab and Budigalimab Study

We are studying a new combination of livmoniplimab and budigalimab for adults with metastatic urothelial carcinoma who have not responded to prior treatments. The goal is to see if this combination improves survival compared to standard chemotherapy.

Urothelial CarcinomaMetastatic Urothelial CarcinomaEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Osteogenesis Imperfecta: Losartan Therapy Study

We are investigating the right dose of losartan for older adolescents and adults with Osteogenesis Imperfecta. The study aims to see how it affects bone health and quality of life.

Brittle Bone Disease3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineOrthopedics and Traumatology

Diffuse Large B-Cell Lymphoma: Zilovertamab Vedotin with R-CHP

We are studying a new treatment combining zilovertamab vedotin with standard therapy for people with diffuse large B-cell lymphoma. The goal is to see if this combination works better than another treatment option.

Diffuse Large B-Cell Lymphoma>2 yearsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Ischemic Stroke: DOAC Intravenous Thrombolysis Trial

We are studying whether intravenous thrombolysis is more effective than standard care for patients with ischemic stroke who have recently taken direct oral anticoagulants. This research aims to improve recovery outcomes for these patients.

Acute Ischemic Stroke>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNeurology

CRD-4730 for Catecholaminergic Polymorphic Ventricular Tachycardia

We are studying a new medication, CRD-4730, to see if it is safe and tolerable for people with CPVT. The trial will also assess its effects on heart rhythm during exercise.

Catecholaminergic Polymorphic Ventricular TachycardiaEfficacy phase (II)Investigational MedicinesPartially RemoteCardiologyHematologyInternal Medicine

IVF Success: Exercise and Mediterranean Diet vs. Aspirin

We are studying whether exercise and a Mediterranean diet can improve live birth rates compared to aspirin for women undergoing in vitro fertilization. This research aims to find better ways to support fertility.

Women's Infertility>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteCardiologyGynecology and Obstetrics

Chronic Spontaneous Urticaria and Hidradenitis Suppurativa: INF904 Study

We are evaluating the safety of an oral medication called INF904 for people with moderate to severe chronic spontaneous urticaria or hidradenitis suppurativa. This study will help us understand how the medication works in the body.

Chronic Spontaneous UrticariaHidradenitis Suppurativa≤3 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Kidney Disease: VX-147 Study for APOL1 Variants

We are testing the safety and effectiveness of VX-147 in adults and children with APOL1-mediated proteinuric kidney disease. The study aims to see if this treatment can improve kidney function and reduce related health risks.

APOL1-mediated Proteinuric Kidney Disease>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNephrology

Carotid Artery Disease: [18F]AlF-NOTA-octreotide PET/MRI Study

We are exploring a new imaging method to better understand carotid artery disease in patients who have had a recent stroke or TIA. This study aims to see if it can help identify those at risk for future strokes.

Carotid Artery Atherosclerosis>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyNeurology

Chronic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with chronic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Chronic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology

Ghrelin for Acute Ischemic Stroke Treatment

We are studying whether ghrelin can improve recovery in patients with acute ischemic stroke treated with endovascular thrombectomy. The trial will also assess its effects on overall health and safety over several days.

Ischemic Stroke1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyNeurology

Episodic Migraine: Xeomin Injections

We are studying Xeomin injections to see if they can help reduce the number of migraine days for people with episodic migraines. This trial compares Xeomin to a placebo to evaluate its effectiveness and safety.

Episodic Migraine6-12 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesPartially RemoteNeurology

Heart Failure: CDR132L Treatment Study

We are comparing a new treatment, CDR132L, with a placebo for people with heart failure and left ventricular hypertrophy. The goal is to see if it improves heart function and structure better than standard care.

Heart Failure with Reduced Ejection Fraction6-12 monthsEfficacy phase (II)>20 visitsPartially RemoteCardiologyInternal Medicine